File Download
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1038/s41388-020-1210-y
- Scopus: eid_2-s2.0-85079719153
- PMID: 32066877
- WOS: WOS:000514052700005
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Phosphorylation independent eIF4E translational reprogramming of selective mRNAs determines tamoxifen resistance in breast cancer
Title | Phosphorylation independent eIF4E translational reprogramming of selective mRNAs determines tamoxifen resistance in breast cancer |
---|---|
Authors | |
Keywords | AK 47 cell line breast cancer breast cancer cell line cancer resistance controlled study |
Issue Date | 2020 |
Publisher | Springer Nature [academic journals on nature.com]. The Journal's web site is located at http://www.nature.com/onc |
Citation | Oncogene, 2020, v. 39, p. 3206-3217 How to Cite? |
Abstract | Eukaryotic translation initiation factor 4E (eIF4E) selectively promotes translation of mRNAs with atypically long and structured 5′-UTRs and has been implicated in drug resistance. Through genome-wide transcriptome and translatome analysis we revealed eIF4E overexpression could promote cellular activities mediated by ERα and FOXM1 signalling pathways. Whilst eIF4E overexpression could enhance the translation of both ERα and FOXM1, it also led to enhanced transcription of FOXM1. Polysome fractionation experiments confirmed eIF4E could modulate the translation of ERα and FOXM1 mRNA. The enhancement of FOXM1 transcription was contingent upon the presence of ERα, and it was the high levels of FOXM1 that conferred Tamoxifen resistance. Furthermore, tamoxifen resistance was conferred by phosphorylation independent eIF4E overexpression. Immunohistochemistry on 134 estrogen receptor (ER+) primary breast cancer samples confirmed that high eIF4E expression was significantly associated with increased ERα and FOXM1, and significantly associated with tamoxifen resistance. Our study uncovers a novel mechanism whereby phosphorylation independent eIF4E translational reprogramming in governing the protein synthesis of ERα and FOXM1 contributes to anti-estrogen insensitivity in ER+ breast cancer. In eIF4E overexpressing breast cancer, the increased ERα protein expression in turn enhances FOXM1 transcription, which together with its increased translation regulated by eIF4E, contributes to tamoxifen resistance. Coupled with eIF4E translational regulation, our study highlights an important mechanism conferring tamoxifen resistance via both ERα dependent and independent pathways. |
Description | Hybrid open access |
Persistent Identifier | http://hdl.handle.net/10722/287187 |
ISSN | 2023 Impact Factor: 6.9 2023 SCImago Journal Rankings: 2.334 |
PubMed Central ID | |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Gong, C | - |
dc.contributor.author | Tsoi, H | - |
dc.contributor.author | Mok, KC | - |
dc.contributor.author | Cheung, J | - |
dc.contributor.author | Man, EPS | - |
dc.contributor.author | Fujino, K | - |
dc.contributor.author | Wong, A | - |
dc.contributor.author | Lam, EWF | - |
dc.contributor.author | Khoo, US | - |
dc.date.accessioned | 2020-09-22T02:57:08Z | - |
dc.date.available | 2020-09-22T02:57:08Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | Oncogene, 2020, v. 39, p. 3206-3217 | - |
dc.identifier.issn | 0950-9232 | - |
dc.identifier.uri | http://hdl.handle.net/10722/287187 | - |
dc.description | Hybrid open access | - |
dc.description.abstract | Eukaryotic translation initiation factor 4E (eIF4E) selectively promotes translation of mRNAs with atypically long and structured 5′-UTRs and has been implicated in drug resistance. Through genome-wide transcriptome and translatome analysis we revealed eIF4E overexpression could promote cellular activities mediated by ERα and FOXM1 signalling pathways. Whilst eIF4E overexpression could enhance the translation of both ERα and FOXM1, it also led to enhanced transcription of FOXM1. Polysome fractionation experiments confirmed eIF4E could modulate the translation of ERα and FOXM1 mRNA. The enhancement of FOXM1 transcription was contingent upon the presence of ERα, and it was the high levels of FOXM1 that conferred Tamoxifen resistance. Furthermore, tamoxifen resistance was conferred by phosphorylation independent eIF4E overexpression. Immunohistochemistry on 134 estrogen receptor (ER+) primary breast cancer samples confirmed that high eIF4E expression was significantly associated with increased ERα and FOXM1, and significantly associated with tamoxifen resistance. Our study uncovers a novel mechanism whereby phosphorylation independent eIF4E translational reprogramming in governing the protein synthesis of ERα and FOXM1 contributes to anti-estrogen insensitivity in ER+ breast cancer. In eIF4E overexpressing breast cancer, the increased ERα protein expression in turn enhances FOXM1 transcription, which together with its increased translation regulated by eIF4E, contributes to tamoxifen resistance. Coupled with eIF4E translational regulation, our study highlights an important mechanism conferring tamoxifen resistance via both ERα dependent and independent pathways. | - |
dc.language | eng | - |
dc.publisher | Springer Nature [academic journals on nature.com]. The Journal's web site is located at http://www.nature.com/onc | - |
dc.relation.ispartof | Oncogene | - |
dc.rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. | - |
dc.subject | AK 47 cell line | - |
dc.subject | breast cancer | - |
dc.subject | breast cancer cell line | - |
dc.subject | cancer resistance | - |
dc.subject | controlled study | - |
dc.title | Phosphorylation independent eIF4E translational reprogramming of selective mRNAs determines tamoxifen resistance in breast cancer | - |
dc.type | Article | - |
dc.identifier.email | Tsoi, H: tsoiho@hku.hk | - |
dc.identifier.email | Man, EPS: ellenman@hku.hk | - |
dc.identifier.email | Khoo, US: uskhoo@hku.hk | - |
dc.identifier.authority | Khoo, US=rp00362 | - |
dc.description.nature | published_or_final_version | - |
dc.identifier.doi | 10.1038/s41388-020-1210-y | - |
dc.identifier.pmid | 32066877 | - |
dc.identifier.pmcid | PMC7142019 | - |
dc.identifier.scopus | eid_2-s2.0-85079719153 | - |
dc.identifier.hkuros | 314322 | - |
dc.identifier.volume | 39 | - |
dc.identifier.spage | 3206 | - |
dc.identifier.epage | 3217 | - |
dc.identifier.isi | WOS:000514052700005 | - |
dc.publisher.place | United Kingdom | - |
dc.identifier.issnl | 0950-9232 | - |